

F1	AGAGGATCCCCGGGTACCGGTAGAAAAAATGAGTAAAGGA
F2	GAAGAACTTTTCACTGGAGTTGTCCCAATTCTTGTTGAAT
F3	TAGATGGTGTATGTTAACGGGCACAAATTTTCTGTCAGTGG
F4	AGAGGGTGAAGGTGATGCAACATACGGAAAACCTACCCTT
F5	AAATTTATTTGCACTACTGGAAAACCTGTTCCATGGC
F6	CAAACTTGTCACTACTTTTCTTATGGTGTTCATGCTT
F7	TTCCCGTTATCCGGATCATATGAAACGGCATGACTTTTTTC
F8	AAGAGTGCCATGCCCCGAAGGTTATGTACAGGAACGCACTA
F9	TATCTTTCAAAGATGACGGGAACTACAAGACGCGTGCTGA
F10	AGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATCGAG
F11	TTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCG
F12	GACACAACTCGAGTACAACTATAACTCACACAATGTATA
F13	CATCACGGCAGACAAAACAAAAGAATGGAATCAAAGCTAAC
F14	TTCAAATTCGCCACAACATTGAAGATGGAAGCGTTCAAC
F15	TAGCAGACCATTATCAACAAAATACTCCAATTGGCGATGG
F16	CCCTGTCCTTTTACCAGACAACCATTACCTGTGACACAA
F17	TCTGCCCTTTTCGAAAGATCCCAACGAAAAGCGTGACCACA
F18	TGGTCCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACA
F19	TGGCATGGATGAGCTCTACAAATAATGAATTCCAACCTGAG
R1	CTCAGTTGGAATTCATTATT
R2	TGTAGAGCTCATCCATGCCATGTGTAATCCCAGCAGCAGT
R3	TACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTG
R4	GGATCTTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGT
R5	TGTCTGGTAAAAGGACAGGGCCATCGCCAATTGGAGTATT
R6	TTGTTGATAATGGTCTGCTAGTTGAACGCTTCCATCTTCA
R7	ATGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATTCT
R8	TTTGTGTTGTCTGCCGTGATGTATACATTGTGTGAGTTATA
R9	GTTGTACTCGAGTTTGTGTCCGAGAATGTTTCCATCTTCT
R10	TTAAAATCAATACCTTTTAACTCGATACGATTAACAAGGG
R11	TATCACCTTCAAACCTTGACTTCAGACGCGTCTTGTAGTT
R12	CCCGTCATCTTTGAAAGATATAGTGCGTTCCTGTACATAA
R13	CCTTCGGGCATGGCACTCTTGAAAAAGTCATGCCGTTTCA
R14	TATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGA
R15	GAAAGTAGTGACAAGTGTGGCCATGGAACAGGTAGTTTT
R16	CCAGTAGTGCAAATAAATTTAAGGGTAAGTTTTCCGTATG
R17	TTGCATCACCTTCACCCTCTCCACTGACAGAAAATTTGTG
R18	CCCGTTAACATCACCATCTAATTCAACAAGAATTGGGACA
R19	ACTCCAGTGAAAAGTTCTTCTCCTTTACTCATTTTTTCTA
R20	CCGGTACCCGGGGATCCTCT
R20RC	AGAGGATCCCCGGGTACCGG

Supplementary Table 1. Oligonucleotides used in *GFPuv* assembly and amplification. All Oligos were purchased from Qiagen with ‘salt-free’ purification. Oligos F1-19 and R1-20 were used to assemble *GFPuv*. Assembly product was amplified using primers R1 and R20RC.